Join the Respiratory Syncytial Virus group to help and get support from people like you.
Respiratory Syncytial Virus News (Page 3)
Related terms: Bronchiolitis, RSV
CDC Strengthens RSV Vaccine Advice for Those Over 75
THURSDAY, June 27, 2024 – In new vaccination guidance issued Wednesday, U.S. health officials now recommend that all Americans aged 75 and older get an RSV vaccine before fall arrives. However,...
Marked Increase in Pediatric RSV Hospitalizations Seen Postpandemic
TUESDAY, June 18, 2024 – Hospital volumes for pediatric respiratory syncytial virus (RSV) rose significantly following the pandemic, along with the need for advanced respiratory support in older...
FDA Approves mRESVIA (respiratory syncytial virus vaccine) for Prevention of Lower Respiratory Tract Disease Caused by RSV
CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) has approved mRESVIA (mRNA-1345), an mRNA respiratory...
U.S. FDA Approves Abrysvo, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Infants Through Active Immunization of Pregnant Individuals 32-36 Weeks of Gestational Age
NEW YORK--(BUSINESS WIRE) August 21, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...
FDA Approves Beyfortus (nirsevimab) for the Prevention of RSV Lower Respiratory Tract Disease in Infants
July 17, 2023 – AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns ...
FDA Approves Abrysvo (respiratory syncytial virus vaccine) for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults
NEW YORK--(BUSINESS WIRE) May 31, 2023 – Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved Abrysvo™ (Respiratory Syncytial Virus Vaccine), the c...